Tre­vi gets $50M and David Meek­er as its new chair­man; Spark in line for a PRV

Tre­vi Ther­a­peu­tics in New Haven, CT has raised a $50.5 mil­lion C round. The biotech has been push­ing a drug called Nal­buphine ER through mid-stage tri­als, gath­er­ing da­ta on its abil­i­ty to re­duce itch­ing caused by a range of con­di­tions. And for­mer Sanofi-Gen­zyme chief David Meek­er is tak­ing the chair­man’s post as part of the fi­nanc­ing. New En­ter­prise As­so­ciates led the fi­nanc­ing round, which in­clud­ed new in­vestors Lund­beck­fonden Ven­tures, Omega Funds and Aper­ture Ven­ture Part­ners, along with TPG Biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.